BridgeBio Pharma shares rise on regulatory filing and rare-disease trial data

Encaleret NDA submission signals ambition to build second commercial franchise beyond Attruby

Shares in BridgeBio Pharma (BBIO) rose 5.8 per cent on Monday after the rare-disease specialist submitted a New Drug Application to the FDA for encaleret and reported strong late-stage clinical data across two programmes, raising hopes that the company is evolving beyond its dependence on a single product.

The dual catalyst — an NDA filing for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) and positive phase 3 data for acoramidis in transthyretin amyloid cardiomyopathy — offered investors the most tangible evidence yet that BridgeBio can convert its rare-disease pipeline into multiple commercial franchises.

The encaleret data are striking. In the CALIBRATE trial, 76 per cent of patients reached target calcium levels on the drug compared with just 4 per cent on conventional therapy. If the FDA grants approval, encaleret would become BridgeBio's first commercial product outside its ATTR franchise, where Attruby has so far anchored the company's revenue story.

The investment case for BridgeBio has long rested on a straightforward but demanding proposition: that management can sustain high cash burn while building out a rare-disease platform capable of generating returns across several indications. The encaleret filing improves that calculus, adding a credible second revenue stream.

Analyst projections span a wide range. Consensus estimates point to revenues of around $2.4bn and earnings of $758mn by 2029, though more bullish forecasters have pencilled in figures as high as $3.4bn in revenue and $1.3bn in earnings — scenarios that assume multiple pipeline successes materialise broadly on schedule.